204 related articles for article (PubMed ID: 24330618)
1. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
2. Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.
Homminga I; Vuerhard MJ; Langerak AW; Buijs-Gladdines J; Pieters R; Meijerink JP
Haematologica; 2012 Feb; 97(2):258-61. PubMed ID: 22058201
[TBL] [Abstract][Full Text] [Related]
3. A novel translocation t(1;5)(p32;q31) that was not associated with the TAL1 rearrangement in a case of T lymphoblastic leukemia/lymphoma.
Cho HS; Kim MK; Bae YK
Korean J Lab Med; 2009 Jun; 29(3):199-203. PubMed ID: 19571616
[TBL] [Abstract][Full Text] [Related]
4. High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.
Wu L; Xu Y; Wang Q; Ruan C; Drexler HG; Wu D; MacLeod RA; Chen S
Haematologica; 2015 Jun; 100(6):e233-6. PubMed ID: 25682596
[No Abstract] [Full Text] [Related]
5. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.
Mendes RD; Sarmento LM; Canté-Barrett K; Zuurbier L; Buijs-Gladdines JG; Póvoa V; Smits WK; Abecasis M; Yunes JA; Sonneveld E; Horstmann MA; Pieters R; Barata JT; Meijerink JP
Blood; 2014 Jul; 124(4):567-78. PubMed ID: 24904117
[TBL] [Abstract][Full Text] [Related]
6. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
7. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic determinants mediate proneness of oncogene breakpoint sites for involvement in TCR translocations.
Larmonie NS; van der Spek A; Bogers AJ; van Dongen JJ; Langerak AW
Genes Immun; 2014 Mar; 15(2):72-81. PubMed ID: 24304972
[TBL] [Abstract][Full Text] [Related]
9. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
10. Novel non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13) activating LMO2 by juxtaposition with MBNL1 and STAG2.
Chen S; Nagel S; Schneider B; Kaufmann M; Meyer C; Zaborski M; Kees UR; Drexler HG; MacLeod RA
Leukemia; 2011 Oct; 25(10):1632-5. PubMed ID: 21647158
[No Abstract] [Full Text] [Related]
11. Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia.
Correia NC; Durinck K; Leite AP; Ongenaert M; Rondou P; Speleman F; Enguita FJ; Barata JT
Leukemia; 2013 Jul; 27(7):1603-6. PubMed ID: 23448994
[No Abstract] [Full Text] [Related]
12. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
13. Translocation t(8;14)(q24;q11) with concurrent PTEN alterations and deletions of STIL/TAL1 and CDKN2A/B in a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis.
Skalska-Sadowska J; Dawidowska M; Szarzyńska-Zawadzka B; Jarmuż-Szymczak M; Czerwińska-Rybak J; Machowska L; Derwich K
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27759908
[TBL] [Abstract][Full Text] [Related]
14. SCL/TAL1: a multifaceted regulator from blood development to disease.
Porcher C; Chagraoui H; Kristiansen MS
Blood; 2017 Apr; 129(15):2051-2060. PubMed ID: 28179281
[TBL] [Abstract][Full Text] [Related]
15. Activation of the
Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
[TBL] [Abstract][Full Text] [Related]
16. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
17. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
18. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.
Valge-Archer VE; Osada H; Warren AJ; Forster A; Li J; Baer R; Rabbitts TH
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8617-21. PubMed ID: 8078932
[TBL] [Abstract][Full Text] [Related]
19. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
[TBL] [Abstract][Full Text] [Related]
20. Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.
Deleuze V; El-Hajj R; Chalhoub E; Dohet C; Pinet V; Couttet P; Mathieu D
PLoS One; 2012; 7(7):e40484. PubMed ID: 22792348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
